[go: up one dir, main page]

WO2010018777A1 - Procédé de lutte contre les mauvaises odeurs - Google Patents

Procédé de lutte contre les mauvaises odeurs Download PDF

Info

Publication number
WO2010018777A1
WO2010018777A1 PCT/JP2009/063922 JP2009063922W WO2010018777A1 WO 2010018777 A1 WO2010018777 A1 WO 2010018777A1 JP 2009063922 W JP2009063922 W JP 2009063922W WO 2010018777 A1 WO2010018777 A1 WO 2010018777A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
pharmaceutical composition
composition according
odor
olmesartan medoxomil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2009/063922
Other languages
English (en)
Japanese (ja)
Inventor
健司 濱浦
晋 長谷川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2010524712A priority Critical patent/JP5688799B2/ja
Publication of WO2010018777A1 publication Critical patent/WO2010018777A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention relates to a method for suppressing the smell of drugs.
  • a pharmaceutical composition containing a specific compound having (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl group hereinafter referred to as “medoxomil group”
  • medoxomil group a specific compound having (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl group
  • An object of the present invention is to provide a preparation capable of reducing the odor of a drug without applying a film coat.
  • the present invention (1) A pharmaceutical composition comprising a drug having a medoxomil group as an active ingredient and cyclodextrin as an additive, (2) The pharmaceutical composition according to (1), wherein the drug having a medoxomil group is olmesartan medoxomil; (3) In (1) or (2), the cyclodextrin is one or more compounds selected from ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin and chemically modified cyclodextrin The pharmaceutical composition described, (4) The pharmaceutical composition according to (1) or (2), wherein the cyclodextrin is one or more compounds selected from ⁇ -cyclodextrin and chemically modified ⁇ -cyclodextrin, (5) The pharmaceutical composition according to (1) or (2), wherein the cyclodextrin is ⁇ -cyclodextrin, (6) The pharmaceutical composition according to any one of (1) to (5), wherein the pharmaceutical composition is a solid preparation, (7) The pharmaceutical composition according to any
  • a sufficient odor reducing effect can be obtained only by adding cyclodextrin to a drug having a medoxomil group, for example, olmesartan medoxomil.
  • the cyclodextrin may be chemically modified in addition to ⁇ , ⁇ , and ⁇ .
  • Examples of the chemically modified cyclodextrin include cyclodextrins such as methylation, acetylation, hydroxypropylation, monochlorotriazination, and sulfobutylation.
  • a plurality of cyclodextrins may be combined.
  • Cyclodextrin may be uniformly contained in the whole pharmaceutical composition, or may be contained in a part of the pharmaceutical composition. When providing a film coating layer, it may be contained in the film coating layer.
  • the active ingredient contained in the pharmaceutical composition is not limited by its structure, degree, mechanism, etc., as long as it is a odorous drug.
  • olmesartan medoxomil 2-amino-5-isobutyl- 4- ⁇ 2- [5- (N, N′-bis ((S) -1-ethoxycarbonyl) ethyl) phosphonamido] furanyl ⁇ thiazole, (5-methyl-2-oxo-1,3-dioxolene-4 -Yl) methyl (5R, 6S) -6-[(R) -1-hydroxyethyl] -2-[(R) -2-tetrahydrofuryl] penem-3-carboxylate, 2-ethoxy-1- ⁇ [ 2 '-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl ⁇ -1H-benzimidazole-7-carbox
  • olmesartan medoxomil 2-amino-5-isobutyl-4- ⁇ 2- [5- (N, N′-bis ((S) -1-ethoxycarbonyl) ethyl) phosphonamido] furanyl ⁇ thiazole or (5 -Methyl-2-oxo-1,3-dioxolen-4-yl) methyl (5R, 6S) -6-[(R) -1-hydroxyethyl] -2-[(R) -2-tetrahydrofuryl] penem -3-carboxylate, particularly preferably olmesartan medoxomil.
  • Olmesartan medoxomil is used for hypertension or a disease derived from hypertension (more specifically, hypertension, heart disease [angina, myocardial infarction, arrhythmia, heart failure or hypertrophy), kidney disease [diabetic nephropathy. , Glomerulonephritis or nephrosclerosis] or cerebrovascular disease [cerebral infarction or cerebral hemorrhage]), and is described in Patent No. 2082519 (US Pat. No. 5,616,599) and the like According to this method, it can be easily manufactured.
  • 2-amino-5-isobutyl-4- ⁇ 2- [5- (N, N'-bis ((S) -1-ethoxycarbonyl) ethyl) phosphonamido] furanyl ⁇ thiazole is a diabetic, hyperglycemic, It is effective for the prevention or treatment of dysfunction, obesity, diabetic complications, etc. (preferably prevention or treatment of diabetes), and can be easily produced according to the method described in International Publication No. 2001/047935 pamphlet etc. it can.
  • (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl (5R, 6S) -6-[(R) -1-hydroxyethyl] -2-[(R) -2- Tetrahydrofuryl] penem-3-carboxylate is a penem compound expected as an antibacterial agent, and can be easily produced according to the method described in International Publication No. 1992/003442 pamphlet or the like.
  • azilsartan medoxomil azilsartan medoxomil, 2-cyclopropyl-1- ⁇ [2 '-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl- 4-yl] methyl ⁇ -1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl or a salt thereof and 2-cyclopropyl-1- ⁇ [2 '-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl ⁇ -1H-benzimidazole-7-carboxylic acid (5-methyl- 2-Oxo-1,3-dioxol-4-yl) methyl or a salt thereof is regarded as a promising therapeutic agent for hypertension and the like, and is disclosed in WO 2005/080384 pamphlet or
  • a compound having a medoxomil group in its molecule such as olmesartan medoxomil, which is a therapeutic agent for hypertension, is converted to an active substance by gradually cleaving the medoxomil ester, whereby a low molecular 2,3-butanedione (hereinafter referred to as “diacetyl”). ”).
  • This diacetyl itself is known as a causative substance of a unique odor, and is considered to be an odor causative substance of a pharmaceutical composition containing a medoxomil group.
  • the pharmaceutical composition in the present invention may contain other active ingredients as necessary.
  • the active ingredient include diuretics such as Trichloromethiazide, Hydrochlorothiazide, Benzylhydrochlorothiazide; Azelnidipine, Amlodipine (including besylate salt), Calcita antagonists such as Benidipine, Nitrendipine, Manidipine, Nicardipine, Nifedipine, Cilnidipine, Efonidipine, Barnidipine, Felodipine (Pioglitazone), rosiglitazone (Rosiglitazone), riboglitazone (Rivoglitazone), MCC-555, NN-2344, BMS-298585, AZ-242, LY-519818, TAK-559 insulin resistance improvers; pravastatin ( Pravastatin), simvastatin, atorvas HMG-CoA reductase inhibitors such as tatorine (A
  • the pharmaceutical composition of the present invention further comprises, as necessary, appropriate pharmacologically acceptable excipients, lubricants, binders, disintegrants, emulsifiers, stabilizers, flavoring agents, diluents, and the like. Additives can be included.
  • Excipients used include, for example, sugar derivatives such as lactose, sucrose, sucrose, mannitol or sorbitol; starch derivatives such as corn starch, potato starch, ⁇ -starch or dextrin; Cellulose derivatives; gum arabic; dextran; or organic excipients such as pullulan; or silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate or magnesium metasilicate aluminate; such as calcium hydrogen phosphate
  • An inorganic excipient such as a phosphate; a carbonate such as calcium carbonate; or a sulfate such as calcium sulfate.
  • lubricants include stearic acid; metal stearates such as calcium stearate or magnesium stearate; talc; colloidal silica; waxes such as bead wax or gay wax; boric acid; adipic acid Sulfate; sodium sulfate; glycol; fumaric acid; sodium stearyl fumarate: sodium benzoate; D, L-leucine; lauryl sulfate such as sodium lauryl sulfate or magnesium lauryl sulfate; anhydrous silicic acid or silicate hydrate Or the above starch derivatives.
  • binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol, or the same compound as the excipient.
  • Disintegrants used include, for example, cellulose derivatives such as low substituted hydroxypropylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium or sodium carboxymethylcellulose; crosslinked polyvinylpyrrolidone; or carboxymethyl starch or carboxymethyl starch Mention may be made of starch and cellulose modified chemically such as sodium.
  • Emsifiers used include, for example, colloidal clays such as bentonite or bee gum; metal hydroxides such as magnesium hydroxide or aluminum hydroxide; anionic surfactants such as sodium lauryl sulfate or calcium stearate A cationic surfactant such as benzalkonium chloride; or a nonionic surfactant such as polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester or sucrose fatty acid ester.
  • colloidal clays such as bentonite or bee gum
  • metal hydroxides such as magnesium hydroxide or aluminum hydroxide
  • anionic surfactants such as sodium lauryl sulfate or calcium stearate
  • a cationic surfactant such as benzalkonium chloride
  • a nonionic surfactant such as polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester or sucrose fatty acid ester.
  • “Stabilizers” used include, for example, parahydroxybenzoates such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; phenol or cresol Such phenols; thimerosal; dehydroacetic acid; or sorbic acid.
  • sweeteners such as sodium saccharin or aspartame
  • acidifiers such as citric acid, malic acid or tartaric acid
  • flavors such as menthol, lemon or orange. it can.
  • Examples of the “diluent” used include lactose, mannitol, glucose, sucrose, calcium sulfate, calcium phosphate, hydroxypropyl cellulose, microcrystalline cellulose, water, ethanol, polyethylene glycol, propylene glycol, glycerol, starch, and polyvinylpyrrolidone. And magnesium aluminate metasilicate or mixtures thereof.
  • the pharmaceutical composition in the present invention is preferably a solid preparation.
  • tablets including sublingual tablets and orally disintegrating tablets
  • capsules including soft capsules and microcapsules
  • granules fine granules
  • powders Pills chewables, lozenges, etc.
  • powders fine granules, granules, capsules or tablets, more preferably tablets, and even more preferably olmesartan medoxomil and It is a tablet containing cyclodextrin uniformly.
  • the preparation method of the present invention includes The Theory and Practice and Pharmacy (Third Edition) (Leon and Lachman and others: LEA and FEBIGER, 1986, pages 3-99 and pages 293-373), Pharmaceutical and Dosage and Forms: Tablets and volumes. (Second Edition) (Herbert A.Lieberman et al .: MARCEL DEKKER INC. 1989, pp. 131-284) .
  • the tablet of the present invention is prepared by, for example, granulating, drying and sizing the active ingredient together with excipients, binders, disintegrants, etc. by a method known per se, adding a lubricant etc., mixing and tableting.
  • the granulation can be carried out by any of wet granulation, dry granulation, and heat granulation methods. Specifically, a high-speed agitation granulator, a fluidized granulator / dryer, an extrusion It is performed using a granulator, a roller compactor, etc.
  • operations such as drying and sizing may be performed as necessary.
  • a mixture of the active ingredient and excipient, binder, disintegrant, lubricant, etc. can also be compressed directly.
  • the tablet of the present invention may be provided with at least one film coating.
  • Coating is performed using, for example, a film coating apparatus, and examples of the film coating base include sugar coating base, water-soluble film coating base, enteric film coating base, sustained-release film coating base, and the like. Can be mentioned.
  • sucrose is used, and one or more kinds selected from talc, precipitated calcium carbonate, calcium phosphate, calcium sulfate, gelatin, gum arabic, polyvinylpyrrolidone, pullulan and the like may be used in combination. it can.
  • water-soluble film coating base examples include cellulose derivatives such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose; polyvinyl acetal diethylaminoacetate, aminoalkyl methacrylate copolymer, polyvinylpyrrolidone, polyvinyl alcohol, Synthetic polymers such as polyvinyl alcohol copolymer; polysaccharides such as pullulan.
  • cellulose derivatives such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylhydroxyethylcellulose, sodium carboxymethylcellulose
  • polysaccharides such as pullulan.
  • enteric film coating bases include cellulose derivatives such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, and cellulose acetate phthalate; methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic Acrylic acid derivatives such as acid copolymer S; natural products such as shellac.
  • sustained-release film coating bases include cellulose derivatives such as ethyl cellulose; acrylic acid derivatives such as aminoalkyl methacrylate copolymer RS, ethyl acrylate / methyl methacrylate / copolymer emulsion, and the like.
  • Two or more of the above coating bases may be mixed and used at an appropriate ratio. Further, if necessary, additives such as appropriate pharmacologically acceptable plasticizers, excipients, lubricants, masking agents, coloring agents, preservatives and the like can be contained.
  • the pharmaceutical composition of the present invention thus obtained may be administered in the same manner as a normal preparation.
  • Test Example 2 In a glass bottle, 100 mg of the untreated olmesartan medoxomil drug substance (Comparative Example 1) or the powdered powder, processed powder, and tablet produced in Example 1 was added as olmesartan medoxomil as it was, sealed, and stored at 40 ° C. for 30 minutes. Thereafter, the glass bottle was opened, and a sensory test of odor was conducted according to the above evaluation criteria by 6 subjects (A to F). The results are shown in Table 2.
  • Test Example 3 500 mg of untreated olmesartan medoxomil drug substance (Comparative Example 1) or the mixed powder prepared in Example 1 as olmesartan medoxomil was placed in a gas chromatography vial (20 mL) and sealed at 40 ° C / 75% RH. Stored for days. Thereafter, the headspace gas was injected into the gas chromatography, and the concentration of the detected gas component (diacetyl) was measured. The results are shown in Table 3. The measurement conditions for gas chromatography are shown below.
  • Example 2 Example 3
  • Example 3 Tablets were prepared by the following method. Olmesartan medoxomil, ⁇ -cyclodextrin (Nippon Shokuhin Kako Co., Ltd.), lactose (Lactochem Co., Ltd.), low-substituted hydroxypropyl cellulose (Shin-Etsu Chemical Co., Ltd.), hydroxypropyl cellulose (Nippon Soda Co., Ltd.) After mixing for 5 minutes with a high-speed agitation granulator (VG-10, Paulek Co., Ltd.), an appropriate amount of purified water was added and granulated for 3 minutes.
  • VG-10 high-speed agitation granulator
  • the obtained granulated product was dried with a fluidized bed dryer (FLO-5M, Freund Sangyo Co., Ltd.). This dried product is sized with a comil (Paurec Co., Ltd.) with a screen with an aperture of about 1 mm, added with crystalline cellulose (Asahi Kasei Chemicals Co., Ltd.), magnesium stearate, and V-type mixer (Tokuju Seisakusho) And mixed for 5 minutes.
  • the mixed granules were tableted with a rotary tableting machine (Kikusui Seisakusho Co., Ltd.) to obtain tablets with a tablet diameter of 8 mm (tablet pressure: 1 ton).
  • the obtained tablets were made into PTP packaging of 10 tablets per sheet (material is unstretched polypropylene, hereinafter referred to as CPP) with a Press Through Package (hereinafter referred to as PTP) packaging machine.
  • Tablets were prepared by the following method. Olmesartan medoxomil, lactose (Lactochem Co., Ltd.), low-substituted hydroxypropyl cellulose (Shin-Etsu Chemical Co., Ltd.), hydroxypropyl cellulose (Nippon Soda Co., Ltd.), high-speed agitation granulator (VG-10, Paulec Co., Ltd.) )) After mixing for 5 minutes, an appropriate amount of purified water was added and granulated for 3 minutes. The obtained granulated product was dried with a fluidized bed dryer (FLO-5M, Freund Sangyo Co., Ltd.).
  • FLO-5M Freund Sangyo Co., Ltd.
  • This dried product is sized with a comil (Paurec Co., Ltd.) with a screen with an aperture of about 1 mm, added with crystalline cellulose (Asahi Kasei Chemicals Co., Ltd.), magnesium stearate, and V-type mixer (Tokuju Seisakusho) And mixed for 5 minutes.
  • the mixed granules were tableted with a rotary tableting machine (Kikusui Seisakusho Co., Ltd.) to obtain tablets with a tablet diameter of 8 mm (tablet pressure: 1 ton).
  • the obtained tablets were made into PTP packaging of 10 tablets per sheet (material is CPP) with a PTP packaging machine.
  • Example 4 The tablets (PTP packaged products) prepared in Example 2, Example 3 and Comparative Example 2 were stored at 25 ° C./75% RH for 1, 2, 3 months.
  • One tablet of the stored PTP package was cut from the PTP sheet, put into a gas chromatography vial (about 20 mL), and sealed. The tablet was taken out from the PTP sheet using a needle, and the gas accumulated in the PTP pocket was uniformly diffused in the vial. Thereafter, the headspace gas was injected into the gas chromatography, and the concentration of the detected gas component (diacetyl) was measured.
  • the measurement conditions for gas chromatography were the same as in Test Example 3. The results are shown in Table 6.
  • Example 5 The tablets (PTP packaged products) prepared in Example 2, Example 3, and Comparative Example 2 were stored at 40 ° C./75% RH for 1 month.
  • One tablet of the stored PTP package was cut out together with the PTP sheet, put into a gas chromatography vial (about 20 mL), and sealed.
  • the tablet was taken out from the PTP sheet using a needle, and the gas accumulated in the PTP pocket was uniformly diffused in the vial. Thereafter, the headspace gas was injected into the gas chromatography, and the concentration (diacetyl) of the detected gas component was measured.
  • the measurement conditions for gas chromatography were the same as in Test Example 3. The results are shown in Table 7.
  • Example 4 (Example 5) (Example 6) An unencapsulated tablet was prepared by the formulation and production method of Comparative Example 2 (the cocoon used R ⁇ having a tablet diameter of 7.5 mm), and a coating solution containing ⁇ -cyclodextrin (Nippon Food Chemical Co., Ltd.) was applied to the coating device ( High coater mini and Freund Sangyo Co., Ltd. were coated with 10 mg or 20 mg as a solid content. The prescription is shown in Table 8.
  • the coating solution is ⁇ -cyclodextrin aqueous solution, Opadry OY-S-9607 (Nihon Colorcon Co., Ltd.) consisting of hypromellose, titanium oxide and talc, or OpadryII 85F48011 consisting of polyvinyl alcohol, titanium oxide, talc and macrogol (Japan) Colorcon Co., Ltd.) was suspended and prepared.
  • Comparative Example 3 (Comparative Example 4) An unencapsulated tablet is produced by the formulation and production method of Comparative Example 2 ( ⁇ uses R ⁇ having a tablet diameter of 7.5 mm), and a coating solution containing no ⁇ -cyclodextrin is applied to a coating device (HiCoater Mini, Freund Sangyo Co., Ltd.) )), 10 mg or 20 mg was coated as a solid content.
  • the prescription is shown in Table 9.
  • the coating solution is Opadry OY-S-9607 (Nihon Colorcon Co., Ltd.) consisting of hypromellose, titanium oxide and talc or OpadryII 85F48011 (Nihon Colorcon Co., Ltd.) consisting of polyvinyl alcohol, titanium oxide, talc and Macrogol. It was prepared by suspending in purified water.
  • Test Example 6 Three tablets prepared in Examples 4, 5, 6, and Comparative Examples 2, 3, and 4 were placed in a gas chromatography vial (20 mL), sealed, and stored at 40 ° C./75% RH for 3 days. . Thereafter, the headspace gas was injected into the gas chromatography, and the concentration of the detected gas component (diacetyl) was measured. The measurement conditions for gas chromatography were the same as in Test Example 3. The results are shown in Table 10. (Table 10) Diacetyl concentration (ng / mL) ND: Not detected
  • a pharmaceutical composition having substantially no unpleasant odor and excellent merchantability can be obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une préparation grâce laquelle il est possible de réduire l'odeur d'un agent médicinal sans l'enrober d'un film. L'invention concerne également une composition médicinale renfermant un composé présentant un groupe médoxomil en tant que composant médicinal ainsi qu'une cyclodextrine en tant qu'additif.
PCT/JP2009/063922 2008-08-11 2009-08-06 Procédé de lutte contre les mauvaises odeurs Ceased WO2010018777A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010524712A JP5688799B2 (ja) 2008-08-11 2009-08-06 におい抑制方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008206998 2008-08-11
JP2008-206998 2008-08-11
JP2008213837 2008-08-22
JP2008-213837 2008-08-22

Publications (1)

Publication Number Publication Date
WO2010018777A1 true WO2010018777A1 (fr) 2010-02-18

Family

ID=41668922

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/063922 Ceased WO2010018777A1 (fr) 2008-08-11 2009-08-06 Procédé de lutte contre les mauvaises odeurs

Country Status (3)

Country Link
JP (2) JP5688799B2 (fr)
TW (1) TW201010699A (fr)
WO (1) WO2010018777A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014188728A1 (fr) * 2013-05-24 2014-11-27 持田製薬株式会社 Composition pour enrobage par film
JP2014224099A (ja) * 2013-04-15 2014-12-04 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
JP2015061828A (ja) * 2013-08-23 2015-04-02 第一三共株式会社 口腔内崩壊錠及びその製造方法
JP2016044170A (ja) * 2014-08-27 2016-04-04 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
JP2016135755A (ja) * 2015-01-15 2016-07-28 大原薬品工業株式会社 メドキソミル基を有するプロドラッグを含有するフィルムコーティング製剤
JP2017001999A (ja) * 2015-06-12 2017-01-05 富士フイルム株式会社 薬物含有粒子の製造方法、薬物含有粒子、医薬組成物、及び口腔内崩壊錠
WO2017164208A1 (fr) * 2016-03-24 2017-09-28 第一三共株式会社 Médicament pour le traitement d'une maladie rénale

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240031121A (ko) * 2022-08-31 2024-03-07 (주)셀트리온 이중 냄새 차폐 약학 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01197432A (ja) * 1988-01-29 1989-08-09 Takeda Chem Ind Ltd 糖衣液、糖衣層及びその形成法
WO2006123766A1 (fr) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Preparation recouverte d’un film contenant du dextrose
WO2006123765A1 (fr) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Preparation recouverte d’un film
JP2007063142A (ja) * 2005-08-29 2007-03-15 Izumi Yakuhin Kogyo Kk 素錠とコーティング層からなる丸剤または錠剤
WO2007097452A1 (fr) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited Emballage-coque à usage médical

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61257923A (ja) * 1985-05-10 1986-11-15 Takeda Chem Ind Ltd 固型状医薬組成物
JP2602712B2 (ja) * 1989-02-14 1997-04-23 メルシャン株式会社 ヘム鉄含有組成物
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
JP2002187842A (ja) * 2000-12-19 2002-07-05 Toyo Shinyaku:Kk ケール加工品およびその加工方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01197432A (ja) * 1988-01-29 1989-08-09 Takeda Chem Ind Ltd 糖衣液、糖衣層及びその形成法
WO2006123766A1 (fr) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Preparation recouverte d’un film contenant du dextrose
WO2006123765A1 (fr) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Preparation recouverte d’un film
JP2007063142A (ja) * 2005-08-29 2007-03-15 Izumi Yakuhin Kogyo Kk 素錠とコーティング層からなる丸剤または錠剤
WO2007097452A1 (fr) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited Emballage-coque à usage médical

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014224099A (ja) * 2013-04-15 2014-12-04 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
WO2014188728A1 (fr) * 2013-05-24 2014-11-27 持田製薬株式会社 Composition pour enrobage par film
JPWO2014188728A1 (ja) * 2013-05-24 2017-02-23 持田製薬株式会社 フィルムコーティング用組成物
JP2015061828A (ja) * 2013-08-23 2015-04-02 第一三共株式会社 口腔内崩壊錠及びその製造方法
JP2016044170A (ja) * 2014-08-27 2016-04-04 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
JP2016135755A (ja) * 2015-01-15 2016-07-28 大原薬品工業株式会社 メドキソミル基を有するプロドラッグを含有するフィルムコーティング製剤
JP2017001999A (ja) * 2015-06-12 2017-01-05 富士フイルム株式会社 薬物含有粒子の製造方法、薬物含有粒子、医薬組成物、及び口腔内崩壊錠
WO2017164208A1 (fr) * 2016-03-24 2017-09-28 第一三共株式会社 Médicament pour le traitement d'une maladie rénale

Also Published As

Publication number Publication date
JP2015017136A (ja) 2015-01-29
JPWO2010018777A1 (ja) 2012-01-26
JP5688799B2 (ja) 2015-03-25
JP5854571B2 (ja) 2016-02-09
TW201010699A (en) 2010-03-16

Similar Documents

Publication Publication Date Title
JP5854571B2 (ja) におい抑制方法
JP5660544B2 (ja) 安定性が向上したアムロジピン及びロサルタンを含む固形薬剤的組成物
CA2654493C (fr) Comprime renfermant du candesartan cilexetil
WO2005117841A1 (fr) Formulation de comprime revetu et procede correspondant
JPWO2009057569A1 (ja) フィルムコーティング製剤
JP5000491B2 (ja) フィルムコーティング製剤
JP2014024874A (ja) 圧縮製剤
JP2018039823A (ja) メントールウィスカーの析出を抑制する方法
CN101180052B (zh) 含有右旋糖的薄膜包衣制剂
EP3307249A1 (fr) Composition pharmaceutique comprenant du chlorhydrate d'ivabradine et procédé pour la préparer
WO2020111089A1 (fr) Composition pharmaceutique
JPWO2014188728A1 (ja) フィルムコーティング用組成物
JP6336651B1 (ja) 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
TW202421201A (zh) 雙重氣味掩蔽醫藥組成物
JP6927663B2 (ja) 固形製剤包装体、及び固形製剤の臭い除去方法
JP2016124871A (ja) オルメサルタンメドキソミル含有錠剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09806669

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010524712

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09806669

Country of ref document: EP

Kind code of ref document: A1